Whereas most previous studies were focused on GLP-1 as a therapeutic agent for the treatment of diabetes and obesity [11,12,13,14,15,16,30,38], we measured the circulating GLP-1 levels in the body under the fasting state. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.